Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer’s disease treatment
Alzheimer’s disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induc...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Dementia |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frdem.2025.1605051/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699873296744448 |
|---|---|
| author | Xenia Androni Rachel J. Boyd Rachel J. Boyd Rachel J. Boyd Paul B. Rosenberg Paul B. Rosenberg Vasiliki Mahairaki Vasiliki Mahairaki |
| author_facet | Xenia Androni Rachel J. Boyd Rachel J. Boyd Rachel J. Boyd Paul B. Rosenberg Paul B. Rosenberg Vasiliki Mahairaki Vasiliki Mahairaki |
| author_sort | Xenia Androni |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induced by these compounds, making them promising therapeutic candidates for AD. In this mini review, we will briefly summarize the existing literature using human cerebral organoids to study the molecular and metabolic changes caused by various psychedelic compounds, focusing on their potential therapeutic applications for AD. |
| format | Article |
| id | doaj-art-b2378a3592b740d697a90bb3090b39b3 |
| institution | DOAJ |
| issn | 2813-3919 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Dementia |
| spelling | doaj-art-b2378a3592b740d697a90bb3090b39b32025-08-20T03:18:27ZengFrontiers Media S.A.Frontiers in Dementia2813-39192025-08-01410.3389/frdem.2025.16050511605051Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer’s disease treatmentXenia Androni0Rachel J. Boyd1Rachel J. Boyd2Rachel J. Boyd3Paul B. Rosenberg4Paul B. Rosenberg5Vasiliki Mahairaki6Vasiliki Mahairaki7Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United StatesDepartment of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United StatesDivision of Geriatric Medicine and Gerontology, Johns Hopkins School of Medicine, Baltimore, MD, United StatesThe Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease, Johns Hopkins School of Medicine, Baltimore, MD, United StatesThe Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease, Johns Hopkins School of Medicine, Baltimore, MD, United StatesDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD, United StatesDepartment of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United StatesThe Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease, Johns Hopkins School of Medicine, Baltimore, MD, United StatesAlzheimer’s disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induced by these compounds, making them promising therapeutic candidates for AD. In this mini review, we will briefly summarize the existing literature using human cerebral organoids to study the molecular and metabolic changes caused by various psychedelic compounds, focusing on their potential therapeutic applications for AD.https://www.frontiersin.org/articles/10.3389/frdem.2025.1605051/fullAlzheimer’s diseasebrain organoidspsychedelicsstem cellsneuroplasticity |
| spellingShingle | Xenia Androni Rachel J. Boyd Rachel J. Boyd Rachel J. Boyd Paul B. Rosenberg Paul B. Rosenberg Vasiliki Mahairaki Vasiliki Mahairaki Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer’s disease treatment Frontiers in Dementia Alzheimer’s disease brain organoids psychedelics stem cells neuroplasticity |
| title | Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer’s disease treatment |
| title_full | Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer’s disease treatment |
| title_fullStr | Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer’s disease treatment |
| title_full_unstemmed | Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer’s disease treatment |
| title_short | Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer’s disease treatment |
| title_sort | psychedelics meet human brain organoids insights into proteomics and potential for alzheimer s disease treatment |
| topic | Alzheimer’s disease brain organoids psychedelics stem cells neuroplasticity |
| url | https://www.frontiersin.org/articles/10.3389/frdem.2025.1605051/full |
| work_keys_str_mv | AT xeniaandroni psychedelicsmeethumanbrainorganoidsinsightsintoproteomicsandpotentialforalzheimersdiseasetreatment AT racheljboyd psychedelicsmeethumanbrainorganoidsinsightsintoproteomicsandpotentialforalzheimersdiseasetreatment AT racheljboyd psychedelicsmeethumanbrainorganoidsinsightsintoproteomicsandpotentialforalzheimersdiseasetreatment AT racheljboyd psychedelicsmeethumanbrainorganoidsinsightsintoproteomicsandpotentialforalzheimersdiseasetreatment AT paulbrosenberg psychedelicsmeethumanbrainorganoidsinsightsintoproteomicsandpotentialforalzheimersdiseasetreatment AT paulbrosenberg psychedelicsmeethumanbrainorganoidsinsightsintoproteomicsandpotentialforalzheimersdiseasetreatment AT vasilikimahairaki psychedelicsmeethumanbrainorganoidsinsightsintoproteomicsandpotentialforalzheimersdiseasetreatment AT vasilikimahairaki psychedelicsmeethumanbrainorganoidsinsightsintoproteomicsandpotentialforalzheimersdiseasetreatment |